Short-term Bactericidal Effect of Contezolid in MAC-PD

The goal of this clinical trial is to learn if contezolid works to treat mycobacterium avium complex pulmonary disease in adults. It will also learn about the safety of contezolid. The main questions it aims to answer are: Does adding contezolid to standard regimen further decrease the bacterial load in patients' sputum compared with current standard regimen? What medical problems do participants have when taking contezolid along with standard regimen? Researchers will compare standard regimen plus contezolid to standard regimen alone to see if contezolid helps further lower the count of bacteria in patients' sputum. Participants will: Take contezolid and standard regimen (azithromycin, ethambutol and rifampicin) or standard regimen only for 6 months, contezolid is administered every day while other drugs are taken 3 times a week Visit the clinic once every 1 month for checkups and tests.

NCT Number	NCT07084402
Lead Sponsor	Bin Cao Collaborators: Beijing Chest Hospital, Capital Medical University, Jiangxi Chest Hospital, MicuRx
Conditions	Mycobacterium Avium Complex Pulmonary Disease
Enrollment	188 participants
Start Date	2025-07-24
Primary Completion	2027-07-24 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-09-18